Carfilzomib functions by selectively and irreversibly binding to the proteasome, an enzyme complex responsible for degrading unneeded or damaged proteins. By inhibiting this complex, carfilzomib causes an accumulation of these proteins, leading to cell death in rapidly dividing cancer cells. This mechanism is particularly effective in multiple myeloma, where malignant plasma cells proliferate uncontrollably.
